Objectives: Correlation of serum trough infliximab levels and antibodies to infliximab (anti-infliximab) with clinical response in Ankylosing Spondylitis (AS).
Methods: According to the international assessments in Ankylosing Spondylitis (ASAS) consensus statement patients were treated with infliximab (5 mg/kg) every 6 weeks after a starting regimen. Preinfusion sera were collected at baseline, 24 and 54 weeks. During every visit ASAS 20% response was assessed, additionally laboratory tests were performed.
Results: After 24 weeks of treatment 24 patients out of 38 (63%) fulfilled ASAS 20% response criteria and 21 (53%) after 54 weeks. After 54 weeks 11 (29%) patients showed undetectable serum trough infliximab levels and detectable anti-infliximab; six of these patients developed an infusion reaction. Anti-infliximab was significantly more often found in ASAS 20% non-responders compared to responders at week 54 (p=0.036). The serum trough infliximab levels of patients with anti-infliximab were significantly lower (mean: 0.02 mg/l) than in patients without anti-infliximab (mean: 12.7 mg/l) (p<0.0001).
Conclusions: In AS, high levels of serum trough infliximab correlated with a good clinical response. Detection of anti-infliximab within 54 weeks is associated with undetectable serum trough infliximab levels, a reduced response to treatment and an increased risk of developing an infusion reaction.
- antibodies to infliximab
- spondylitis, ankylosing
- tumor necrosis factor-alpha
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.